| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 04/27/2004 | US6727256 4-aminoquinazoline derivatives as anticarcinogenic agents |
| 04/27/2004 | US6727255 Brain, nervous system and psychological disorders |
| 04/27/2004 | US6727254 8-(bis-(phenyl) methyl)-3-heteroaryl-8-azabicyclo-(3.2.1)octan-3-ols and derivatives, useful in treating pain, anxiety, cough, asthma, depresion and alcohol abuse |
| 04/27/2004 | US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 04/27/2004 | US6727245 Heterobicyclic derivatives |
| 04/27/2004 | US6727241 Inhibit the binding of various chemokines, such as mip-1 alpha and rantes, to the ccr1 receptor |
| 04/27/2004 | US6727239 Inhibitory activity on no- synthase enzymes producing nitrogen monoxide no and/or an activity which traps the reactive oxygen species (ros) |
| 04/27/2004 | US6727226 Conotoxin peptide extracted from the venom of a marine snail, conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics |
| 04/27/2004 | US6727064 Antiinflammatory agents; anticarcinogenic agents |
| 04/27/2004 | US6726925 Bi-layer membrane comprising phospholipid and lysolipid; drug delivery, medical diagnosis |
| 04/27/2004 | CA2140368C (3r,4r)-.delta.6-tetrahydrocannabinol-7-oic acids |
| 04/27/2004 | CA2118929C (3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them |
| 04/27/2004 | CA2058370C Monoclonal antibodies against human tumor necrosis factor .alpha. |
| 04/22/2004 | WO2004033620A2 Methods and compositions for therapeutic use of rna interference |
| 04/22/2004 | WO2004033473A1 Glucose-based compounds with affinity to p-selectin |
| 04/22/2004 | WO2004033436A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
| 04/22/2004 | WO2004033435A1 Quinazolinone derivatives useful as anti-hyperalgesic agents |
| 04/22/2004 | WO2004032964A1 Remedies for allergic diseases |
| 04/22/2004 | WO2004032918A1 Treatment of inflammatory conditions with ∝-3 polyunsaturated fatty acids |
| 04/22/2004 | WO2004032900A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | WO2004032840A2 Compounds, compositions, and methods |
| 04/22/2004 | WO2004020430A3 Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics |
| 04/22/2004 | WO2004020410A3 Dihydropyridinone derivatives as hne inhibitors |
| 04/22/2004 | WO2004018431A3 Novel phenanthridines |
| 04/22/2004 | WO2004017948A3 Use of lck inhibitor for treatment of immunologic diseases |
| 04/22/2004 | WO2004016597A3 Protein kinase inhibitors and uses thereof |
| 04/22/2004 | WO2004013077A3 Cyclopentanone and cyclopentanone derivatives as potent activators of hsf-1 |
| 04/22/2004 | WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2004005310A3 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/22/2004 | WO2004005243A3 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 04/22/2004 | WO2003087318A9 Truncated 24 kda basic fibroblast growth factor |
| 04/22/2004 | WO2003068937A3 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 04/22/2004 | WO2003064625A3 Oligonucleotide compositions with enhanced efficiency |
| 04/22/2004 | WO2003057722A3 Cyclic tetrapeptide compound and use thereof |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003005999A8 Methods of treating cytokine mediated diseases |
| 04/22/2004 | WO2002094794A8 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders |
| 04/22/2004 | WO2002074767A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074752A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074748A8 Metalloproteinase inhibitors |
| 04/22/2004 | US20040077877 Jun n-terminal kinase inhibitors |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077858 Making 4-(1H-indol-5-yloxy)-pyrrolo(2,1-f)(1,2,4)triazine compounds that are tyrosine kinase inhibitors; reducing vascular permeability; anticancer agents |
| 04/22/2004 | US20040077854 4-chloro-N-((5-((4-(hexylamino)piperidin-1-yl)sulfonyl)thien-2 -yl)methyl)benzamide for example; JUN kinase inhibitors to treat nervous system disorders, cancer, cardiovascular and autoimmune disorders |
| 04/22/2004 | US20040077828 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 04/22/2004 | US20040077727 Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23 |
| 04/22/2004 | US20040077706 Piperidine and azepine derivatives; anxiolytic, analgesic, antidepressant, antiemetic, antiinflammatory, and hypotensive agents; sexual and psychological disorders; Alzheimer*s, Parkinson*s, Lesche-Nyhane, Wilson*s, and Tourette*s syndrome |
| 04/22/2004 | US20040077704 Fused cyclopenta-, cyclohexa-, or cyclohepta(g)indole derivatives as human non-pancreatic secretory phospholipase inhibitors; antiinflammatory agents |
| 04/22/2004 | US20040077702 Administering indazole derivative; or thienyl-, furyl-, or pyrrolyl- fused pyrazole derivative to treat Alzheimer*s, Parkinson*s, or Huntington*s disease |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077693 Integrin receptor inhibitors |
| 04/22/2004 | US20040077686 Inhibition of cyclooxygenase-2 activity |
| 04/22/2004 | US20040077684 Piperidinyl compounds that selectively bind integrins |
| 04/22/2004 | US20040077680 Ureaacylated indazole, benzisoxazole, or benzisothiazole derivative with monocyte chemoattractant protein inhibitors; antiinflammatory agents; autoimmune diseases; arthritis, asthma, atherosclerosis, diabetes |
| 04/22/2004 | US20040077678 Urea substituted imidazoquinoline ethers |
| 04/22/2004 | US20040077670 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/22/2004 | US20040077668 Compounds, compositins, and methods |
| 04/22/2004 | US20040077665 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof |
| 04/22/2004 | US20040077658 Respiratory system, nervous system, brain, gastrointestinal and psychological disorders; chronic obstructive pulmonary disease; antiasthmatics, analgesics |
| 04/22/2004 | US20040077657 HT3 Receptor antagonists; amyotrophic lateral sclerosis, premenstrual tension, obsessive-compulsive disorder; Parkinson*s, Alzheimer*s, and Huntington*s disease; memory, eating, psychological, and nervous system disorders |
| 04/22/2004 | US20040077649 Novel cannabimimetic ligands |
| 04/22/2004 | US20040077643 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 04/22/2004 | US20040077630 Allosteric adenosine receptor modulators |
| 04/22/2004 | US20040077629 Such as 4-methyl-2-hydroxy-2-(4-hydroxy-4-methylpentyl)-butanediocate ester cephalotaxine derivative |
| 04/22/2004 | US20040077616 Spirocyclopropyl amides and acids and their therapeutic applications |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077610 Medicament containing a polyamine as an active substance |
| 04/22/2004 | US20040077552 Inflammation-inhibiting compounds |
| 04/22/2004 | US20040077535 Novel physiologically active peptide and use thereof |
| 04/22/2004 | US20040076986 A gene and/or a protein involved in the prevention or treatment of allergic diseases and dermatitis |
| 04/22/2004 | US20040076956 Oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with DNA repair which are directed against the sequence; ascertaining genetic and/ or epigenetic parameters of DNA repair genes |
| 04/22/2004 | US20040076683 Can be used for treatment of solid or circulating cancerous tumors; exhibit reduced toxicity compared to free drug in solution, exhibit stealth properties with respect to immune system of host to which they are administered |
| 04/22/2004 | US20040076669 Tramadol-based medicament |
| 04/22/2004 | US20040076648 Antidepressant, an n-methyl-aspartic acid receptor antagonist, a lipophilic component, water and a surfacant; oil in water emulsion |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2501938A1 Compounds, compositions, and methods |
| 04/22/2004 | CA2501801A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
| 04/22/2004 | CA2501529A1 Quinazolinone derivatives useful as anti-hyperalgesic agents |
| 04/22/2004 | CA2498938A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | CA2465860A1 Methods and compositions for therapeutic use of rna interference |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410820A2 Nasal delivery devices |
| 04/21/2004 | EP1410807A1 Methods and compositions useful for inhibition of angiogenesis |
| 04/21/2004 | EP1410800A1 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts |
| 04/21/2004 | EP1410798A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410793A1 Delivery form of sodium ibuprofen |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409715A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409672A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 04/21/2004 | EP1409670A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 04/21/2004 | EP1409668A2 Antisense nucleic acid against alphav integrin |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409643A1 Probiotic lactobacillus casei strains |